MedTrace Logo

Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL

NCT02987400 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2022-02-16

No results posted yet for this study

Summary

The purpose of this study is to evaluate the clinical activity and tolerability of a combination of obinutuzumab plus venetoclax in patients with relapsed or refractory diffuse large B-cell lymphoma.

Conditions

  • Lymphoma, Large B-Cell, Diffuse

Interventions

DRUG

Venetoclax

3 cycles followed by 9 cycles consolidation if not transplant eligible

DRUG

Obinutuzumab

3 cycles followed by 9 cycles consolidation if not transplant eligible

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Arbeitsgemeinschaft medikamentoese Tumortherapie

    lead OTHER

Principal Investigators

  • Ulrich Jäger, MD · Medical University of Vienna

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-04
Primary Completion
2021-10-19
Completion
2021-10-19

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02987400 on ClinicalTrials.gov